{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:40:20Z","timestamp":1793238020467,"version":"4.5.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Private equity investment in US health care, including substance use disorder treatment, has grown. However, the implications of private equity acquisition of substance use disorder treatment facilities for buprenorphine access and quality of care are unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the associations of private equity acquisition of substance use disorder treatment facilities and buprenorphine prescribing patterns.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this cross-sectional study using difference-in-differences analysis, aggregate prescription claims from an analytical dataset for buprenorphine from acquired substance use disorder treatment facilities were compared with those from nonacquired facilities from 2019 quarter 3 through 2021 quarter 2. Prescriptions for buprenorphine filled by adult individuals (aged &amp;gt;18 years) were included in the analyses. An event study difference-in-differences design was used to assess changes in buprenorphine prescribing characteristics at facilities from 4 quarters before to 4 quarters after acquisition using a linear model adjusted for facility, year, and treatment cohort characteristics. Analyses were performed from January 2025 to December 2025.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Patient volume, prescription volume, payer mix, and treatment retention duration.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In a sample of 90 acquired facilities and 2374 never-acquired facilities, private equity acquisition was associated with increases in patient volumes. Acquisition was associated with a mean increase of 65.66 (95% CI, 30.57-100.76;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) patients receiving buprenorphine per facility quarter. Similarly, acquisition was associated with a mean increase of 163.90 (95% CI, 47.07-280.73;\n P<\/jats:italic>\n \u2009=\u2009.006) buprenorphine prescriptions per facility quarter. Acquisition was associated with an increase of 0.73 (95% CI, 0.07-1.40;\n P<\/jats:italic>\n \u2009=\u2009.03) percentage points in prescriptions paid with cash compared with the control group. Other payer types were not associated with acquisition. Measures of treatment episode duration decreased after acquisition, with decreases of 6.24 (95% CI, \u221211.47 to \u22121.00;\n P<\/jats:italic>\n \u2009=\u2009.02) percentage points in 90-day retention and 7.91 (95% CI, \u221213.96 to \u22121.86;\n P<\/jats:italic>\n \u2009=\u2009.01) percentage points in 180-day retention.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n In this study, the volume of patients treated with buprenorphine increased after private equity acquisition, with minimal changes in the payer mix among these patients. However, the quality of treatment, in terms of buprenorphine retention duration, decreased after acquisition. These results underscore the need for oversight mechanisms and continued research to ensure incentives for private investment in addiction care align with delivery of high-quality evidence-based treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.0250","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:00:32Z","timestamp":1772467232000},"page":"e260250","source":"Crossref","is-referenced-by-count":3,"title":["Private Equity Acquisition and Buprenorphine Prescribing"],"prefix":"10.1001","volume":"9","author":[{"given":"Taylor","family":"Holdaway","sequence":"first","affiliation":[{"name":"The Wharton School, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Busch","sequence":"additional","affiliation":[{"name":"Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Reimer","sequence":"additional","affiliation":[{"name":"The Wharton School, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Beetham","sequence":"additional","affiliation":[{"name":"Brown School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fiellin","sequence":"additional","affiliation":[{"name":"Yale School of Public Health, New Haven, Connecticut"},{"name":"Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"King","sequence":"additional","affiliation":[{"name":"The Wharton School, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"7","key":"zoi260020r1","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxae080","article-title":"Acquisitions of behavioral health treatment facilities from 2010 to 2021.","volume":"2","author":"Thornburg","year":"2024","journal-title":"Health Aff Sch"},{"issue":"3","key":"zoi260020r2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamapsychiatry.2019.3880","article-title":"Private equity investment in behavioral health treatment centers.","volume":"77","author":"Brown","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"zoi260020r3","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamapsychiatry.2024.0825","article-title":"Geographic penetration of private equity ownership in outpatient and residential behavioral health.","volume":"81","author":"Zhu","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"zoi260020r4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-075244","article-title":"Evaluating trends in private equity ownership and impacts on health outcomes, costs, and quality: systematic review.","volume":"382","author":"Borsa","year":"2023","journal-title":"BMJ"},{"issue":"7","key":"zoi260020r5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jamapsychiatry.2025.0689","article-title":"Private equity among US psychiatric hospitals.","volume":"82","author":"Shields","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"zoi260020r6","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1007\/s11606-024-09218-3","article-title":"Private equity penetration in behavioral health in the United States, 2010-2022.","volume":"40","author":"Singh","year":"2025","journal-title":"J Gen Intern Med"},{"issue":"5","key":"zoi260020r7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1377\/hlthaff.2020.01535","article-title":"Private equity investments in health care: an overview of hospital and health system leveraged buyouts, 2003-17.","volume":"40","author":"Offodile","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"8","key":"zoi260020r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27488","article-title":"Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021.","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi260020r9","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/add.14188","article-title":"The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom.","volume":"113","author":"Hickman","year":"2018","journal-title":"Addiction"},{"issue":"3","key":"zoi260020r10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.amepre.2021.02.026","article-title":"Association between buprenorphine for opioid use disorder and mortality risk.","volume":"61","author":"Vakkalanka","year":"2021","journal-title":"Am J Prev Med"},{"issue":"1","key":"zoi260020r11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/acps.13477","article-title":"A comparison of mortality rates for buprenorphine versus methadone treatments for opioid use disorder.","volume":"147","author":"Gottlieb","year":"2023","journal-title":"Acta Psychiatr Scand"},{"key":"zoi260020r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209252","article-title":"Quantifying a potential protective effect of buprenorphine on fatality risk during acute fentanyl exposures.","volume":"158","author":"Dai","year":"2024","journal-title":"J Subst Use Addict Treat"},{"issue":"9","key":"zoi260020r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.2886","article-title":"Association of private equity acquisition of physician practices with changes in health care spending and utilization.","volume":"3","author":"Singh","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"6","key":"zoi260020r14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jama.2024.23450","article-title":"Changes in patient care experience after private equity acquisition of US hospitals.","volume":"333","author":"Bhatla","year":"2025","journal-title":"JAMA"},{"issue":"24","key":"zoi260020r15","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1001\/jama.2023.23147","article-title":"Changes in hospital adverse events and patient outcomes associated with private equity acquisition.","volume":"330","author":"Kannan","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"zoi260020r16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1377\/hlthaff.2025.00326","article-title":"Private equity acquiring large shares of the opioid treatment market without changing market-level methadone supply.","volume":"44","author":"Singh","year":"2025","journal-title":"Health Aff (Millwood)"},{"issue":"11","key":"zoi260020r17","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1377\/hlthaff.2025.00444","article-title":"Private equity acquisition of substance use treatment centers increases probability of public health insurance acceptance.","volume":"44","author":"Reimer","year":"2025","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"zoi260020r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.16089","article-title":"Pharmacy availability of buprenorphine for opioid use disorder treatment in the US.","volume":"6","author":"Weiner","year":"2023","journal-title":"JAMA Netw Open"},{"key":"zoi260020r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109518","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.","volume":"237","author":"Hill","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"zoi260020r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2025.209633","article-title":"Different forms of stigma and rural primary care professionals\u2019 willingness to prescribe buprenorphine.","volume":"171","author":"Franz","year":"2025","journal-title":"J Subst Use Addict Treat"},{"key":"zoi260020r22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jsat.2018.07.008","article-title":"Comparison between buprenorphine provider availability and opioid deaths among US counties.","volume":"93","author":"Jones","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"zoi260020r27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3122\/jabfm.2018.02.170287","article-title":"Physician multisite practicing: impact on access to care.","volume":"31","author":"Xierali","year":"2018","journal-title":"J Am Board Fam Med"},{"issue":"1","key":"zoi260020r29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/add.15998","article-title":"The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment.","volume":"118","author":"Glanz","year":"2023","journal-title":"Addiction"},{"issue":"2","key":"zoi260020r30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jeconom.2020.09.006","article-title":"Estimating dynamic treatment effects in event studies with heterogeneous treatment effects.","volume":"225","author":"Sun","year":"2021","journal-title":"J Econom"},{"issue":"2","key":"zoi260020r31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1257\/jep.37.2.203","article-title":"An introductory guide to event study models.","volume":"37","author":"Miller","year":"2023","journal-title":"J Econ Perspect"},{"issue":"3","key":"zoi260020r32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jama.2019.18913","article-title":"Trends in buprenorphine treatment in the United States, 2009-2018.","volume":"323","author":"Olfson","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"zoi260020r33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/MLR.0000000000001530","article-title":"Quality of buprenorphine care for insured adults with opioid use disorder.","volume":"59","author":"Anderson","year":"2021","journal-title":"Med Care"},{"issue":"4","key":"zoi260020r34","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/rfs\/hhad082","article-title":"Owner incentives and performance in healthcare: private equity investment in nursing homes.","volume":"37","author":"Gupta","year":"2024","journal-title":"Rev Financ Stud"},{"issue":"11","key":"zoi260020r35","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.3817","article-title":"Association of private equity investment in US nursing homes with the quality and cost of care for long-stay residents.","volume":"2","author":"Braun","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"4","key":"zoi260020r36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.9581","article-title":"Association between hospital private equity acquisition and outcomes of acute medical conditions among Medicare beneficiaries.","volume":"5","author":"Cerullo","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"16","key":"zoi260020r37","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jama.2020.17477","article-title":"Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic.","volume":"324","author":"Ochalek","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"zoi260020r38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.25999","article-title":"Buprenorphine prescribing characteristics following relaxation of X-waiver training requirements.","volume":"7","author":"Christine","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"16","key":"zoi260020r39","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.2020.18543","article-title":"The opioid epidemic during the COVID-19 pandemic.","volume":"324","author":"Haley","year":"2020","journal-title":"JAMA"},{"key":"zoi260020r21","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences, Engineering, and Medicine","year":"2019"},{"key":"zoi260020r23","unstructured":"Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS). Accessed 2023. https:\/\/www.samhsa.gov\/data\/data-we-collect\/n-sumhss-national-substance-use-and-mental-health-services-survey\/datafiles\/n-ssats-2020"},{"key":"zoi260020r24","unstructured":"IQVIA. Available IQVIA data. Accessed September 15, 2025. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/available-iqvia-data"},{"key":"zoi260020r25","unstructured":"Centers for Medicare and Medicaid Services. The Who, What, When, Why & How of NPI: Information for Health Care Providers. Accessed September 15, 2025. https:\/\/www.cms.gov\/medicare\/provider-enrollment-and-certification\/medicareprovidersupenroll\/downloads\/enrollmentsheet_wwwwh.pdf"},{"key":"zoi260020r26","unstructured":"Centers for Medicare and Medicaid Services. Doctors and clinicians: data sources | Provider Data Catalog. Accessed September 18, 2025. https:\/\/data.cms.gov\/provider-data\/topics\/doctors-clinicians\/data-sources"},{"key":"zoi260020r28","unstructured":"RAND Corporation; American Medical Association. Quality ID #468: Continuity of Pharmacotherapy for Opioid Use Disorder (OUD). December 2021. Accessed January 7, 2026. https:\/\/qpp.cms.gov\/docs\/QPP_quality_measure_specifications\/CQM-Measures\/2022_Measure_468_MIPSCQM.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2845671\/holdaway_2026_oi_260020_1772226449.44008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:00:35Z","timestamp":1772467235000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2845671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.0250","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}